

**FINAL
PROGRAMME**



**11TH
INTERNATIONAL
CONGRESS
ON SPONDYLOARTHRITIDES**

**4 - 6 October 2018
Gent, Belgium**

www.spa-congress.org

The essential journal
for timely clinical research

Since it was first established in 1974, The Journal of Rheumatology has been publishing forward-thinking, peer-reviewed clinical research in all fields related to rheumatology.

Sign up for alerts, engage in monthly online discussions on our forum, access editorials and articles without subscriptions, read articles published ahead of print, delve into detailed research only available online, and discover dynamic content in unique custom collections.

Forum | Open Access | First Release | Online Supplements | Custom Collections

Presidents & Committees 4

Welcome Address 5

Scientific Programme

 Thursday, October 4 6

 Friday, October 5 8

 Saturday, October 6..... 11

Poster List

 Poster Session 1 13

 Poster Session 2 21

 Poster Session 3 28

General Information

 Registration 37

 Social Programme 39

 General Information 41

 City Map..... 42

 Sponsors 43



Presidents

Helena Marzo-Ortega (UK) and Maxime Breban (France)

Local Organising Committee

Dirk Elewaut (Belgium)
Filip Van den Bosch (Belgium)

Honorary Scientific Committee

Eric Veys (Belgium – Founder)
Herman Mielants (Belgium – Co-Founder)

Marjatta Leirisalo-Repo (Finland)
Jose A. Lopez de Castro (Spain)
Désirée van der Heijde (The Netherlands)
David Yu (USA)

Scientific Committee

Xenofon Baraliakos (Germany)
Paul Bowness (UK)
Jürgen Braun (Germany)
Matthew Brown (Australia)
Rubén Burgos Vargas (Mexico)
Francesco Ciccia (Italy)
Robert Colbert (USA)
Maria-Antonietta D'Agostino (France)
Atul Deodhar (USA)
Robert Inman (Canada)
Robert Landewé (The Netherlands)
Rik Lories (Belgium)
Walter Maksymowych (Canada)
John Reveille (USA)
Martin Rudwaleit (Germany)
Percival Sampaio-Barros (Brazil)
Georg Schett (Germany)

Speakers and Chairs

All speakers and chairs are invited by the Presidents and the Local Organising Committee.

Dear colleagues and friends,

Welcome to the **Eleventh International Congress on Spondyloarthritis**, taking place on 4 - 6 October 2018 in the beautiful city of Gent.

The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. Indeed, the attendance has almost quadrupled since 1998 to include scientists, medical doctors, allied health professionals, pharmaceutical industry representatives and people affected by these conditions from all over the world.

The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters.


This year's programme offers a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics. A highly regarded part of the meeting are the poster sessions which provide the perfect frame for stimulating and interactive multidisciplinary exchanges among attendees. In addition, and following on from the last edition we have planned a lively debate which promises to be educational as well as entertaining.

New this year is the introduction of the "Gent Oration" aimed to honour a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to invite Professor Joachim Sieper as the inaugural Gent orator in this first edition.

The social programme including the Walking Dinner at the Opening Reception, Gala Dinner and Farewell Reception are sure to give you the opportunity to catch up with old and new friends and enjoy the magic of Gent.

As co-presidents of the 11th International Congress on Spondyloarthritis we would like to welcome you to this exciting occasion which we are sure will once again, provide the best platform for vibrant scientific and clinical discussions in all aspects of these fascinating group of diseases.

Helena Marzo-Ortega & Maxime Breban





- 13.00 **Welcome Address**
Helena Marzo-Ortega & Maxime Breban, Presidents
- 13.15 INV1 **Opening Keynote Lecture**
The role of microbiome in health and chronic inflammation
Dusko Ehrlich, Jouy-en-Josas, France
- SESSION 1: Tackling the microbiome realm in SpA**
Chairs: Dirk Elewaut & Rubén Burgos-Vargas
- 14.00 INV2 **Innate lymphoid cells at the barrier and inflammation: Halt or go?**
Tom Cupedo, Rotterdam, The Netherlands
- 14.30 INV3 **Microbiota in IBD, from inventory to therapeutic intervention**
Harry Sokol, Paris, France
- 15.00 INV4 **Microbiome and gut inflammation in HLA-B27 transgenic rat: What is the relationship?**
Robert Colbert, Bethesda, USA
- 15.30 **Coffee Break**
- SESSION 2: Do women come from Venus and men from Mars? Myths and Truths about gender differences in axial SpA**
Chairs: Irene van der Horst-Bruinsman & Martin Rudwaleit
- 16.00 INV5 **Exploring gender differences in the clinical phenotype and response to treatment in axial SpA**
Lianne Gensler, San Francisco, USA
- 16.30 INV6 **So there may be some true after all: What is the underlying biology?**
Eric Gracey, Toronto, Canada
- 17.00 INV7 **Painful risk to be female? What we know and why it is not so trivial!**
Walter Magerl, Mannheim, Germany

Keynote Lecture - The Gent SpA Oration
Chairs: Helena Marzo-Ortega & Maxime Breban

17.30 INV8 **AS old as time: From bugs to bench to the bedside and back**
Joachim Sieper, Berlin, Germany

18.15 **Walking Dinner**



SESSION 3: Innate cells and cell signaling in SpA

Chairs: Francesco Ciccia & Robert Inman

08.45 INV9 **The importance of unconventional T cells in inflammation and immunity**

Dale Godfrey, Melbourne, Australia

09.15 INV10 **How macrophages help resolve inflammation**

Kodi Ravichandran, Charlottesville, USA & Gent, Belgium

09.45 INV11 **Immune effector cells in SpA: What are the pathways?**

Paul Bowness, Oxford, UK

10.15 **Poster Session 1 and Coffee Break****SESSION 4: The auto-inflammation axis in SpA**

Chairs: Atul Deodhar & Jürgen Braun

11.15 INV12 **Auto-immunity versus auto-inflammation in eye disease in SpA**

John Forrester, Aberdeen, UK

11.45 INV13 **Auto-antigens as drivers of psoriasis: Increasing specificity and efficacy of treatments in skin and joints**

Diamant Thaçi, Lübeck, Germany

SESSION 5: The great debate

Chairs: Filip Van den Bosch & Robert Landewé

12.15 **This house believes that "Treat to target" has no place in the treatment of axSpA**

INV14 Speaking for: Atul Deodhar, Portland, USA

INV15 Speaking against: Pedro Machado, London, UK

13.00 **Lunch****SESSION 6: HLA-B27: Where are we**

Chairs: Robert Colbert & Matthew Brown

14.00 INV16 **How peptide loading complex affects MHC class I biology**

Simon Trowitzsch, Frankfurt am Main, Germany

14.30 INV17 **HLA-B27 and multiomics: Where does it bring us?**

Henri-Jean Garchon, Paris, France

15.00 INV18 **Is fruit fly relevant to SpA?**

Sébastien Gaumer, Paris, France

Selected Oral Presentations I

Chairs: Robert Colbert & Matthew Brown

15.30 01 **Gut dysbiosis in ankylosing spondylitis is associated with increased fecal calprotectin**

Eva Klingberg, Sweden

15.40 02 **Inflammasomes activation occurs in the inflamed tissues of AS patients and drives IL-23 expression and ILC3 expansion**

Francesco Ciccia, Italy

15.50 03 **Transmembrane TNF signaling through TNF-RI induces SpA-like inflammation, whereas signaling through TNF-RII is crucial for new bone formation**

Leonie van Duivenvoorde, The Netherlands

16.00 04 **PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 anti trypsin and beta 2 microglobulin may differentiate ankylosing spondylitis from non radiographic axSpA, mechanical back pain and healthy controls**



Elizabeth Reilly, UK

16.10 05 **Impact of gut involvement in early spondyloarthritis - The DESIR cohort**

Daniel Wendling, France

16.20 06 **Gender differences in TNFi treatment adherence and response in AS patients: A prospective longitudinal cohort study**

Sophie Hoekstra, The Netherlands

16.30 **Poster Session 2 and Coffee Break**

SESSION 7: Genetics, genomics and SpA: The era of new-sequencing technology



Chairs: John Reveille & Paul Bowness

- 17.15 INV19 **Genetic studies in AS: Progress and translation**
Matthew Brown, Brisbane, Australia
- 17.45 INV20 **Lessons from epigenetics for SpA**
Julian Knight, Oxford, UK
- 18.15 INV21 **Operation Transformation: The impact of genes and life style in joint disease**
Donal O'Shea, Dublin, Ireland
- 18.45 **Scientific Committee Meeting**
- 20.00 **Gala Dinner at the Handelsbeurs**
For details, see page 39

Selected Oral Presentations II

Chairs: Rik Lories & Percival Sampaio-Barros

- 08.00 07 **Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow**
Xenofon Baraliakos, Germany
- 08.07 08 **Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals < 45 years in the general population as part of a large community study (SHIP)**
Xenofon Baraliakos, Germany
- 08.15 09 **Validation of ASAS MRI lesion definitions in axial spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort (ECHOSPA)**
Walter Maksymowych, Canada
- 08.25 010 **Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: The 5 years data of the DESIR cohort**
Alexandre Sepriano, The Netherlands
- 08.35 011 **Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active AS: 12-week results from a Phase 2b study**
Désirée van der Heijde, The Netherlands
- 08.45 012 **High need for anti-TNF therapy after withdrawal strategy in early peripheral spondyloarthritis**
Philippe Carron, Belgium
- 08.55 013 **Dutch recommendations for physical therapy in axial spondyloarthritis (axSpA)**
Salima van Weely, The Netherlands



SESSION 8: Bone and SpA: What's new

Chairs: Rik Lories & Percival Sampaio-Barros

09.05 INV22 **Role of ectopic BMP signaling in pathologic ossification and angiogenesis**

Maurizio Pacifici, Philadelphia, USA

09.35 INV23 **Bone control: Gastrointestinal metabolites on a mission...**

Georg Schett, Erlangen, Germany

10.05 INV24 **Mechanical stress, how does it impact SpA?**

Dirk Elewaut, Gent, Belgium

10.35 **Poster Session 3 and Coffee Break****SESSION 9: Heterotopic new bone formation in SpA: The plot thickens...**

Chairs: Walter Maksymowych & Maria-Antonietta D'Agostino

11.15 INV25 **IL-17, TNF and bone formation, what is the evidence?**

Pierre Miossec, Lyon, France

11.45 INV26 **Is low radiation CT of the spine suitable to assess structural progression in SpA?**

Désirée van der Heijde, Leiden, The Netherlands

12.15 INV27 **Do we need to bother measuring bone proliferation in axial SpA? Insights from clinical trials**

Xenofon Baraliakos, Bochum, Germany

12.45 **Closure of the Congress**

Helena Marzo-Ortega & Maxime Breban, Presidents

13.00 **Farewell Reception**

Poster Session 1 is scheduled during the coffee break of 10.15 - 11.15 hrs on Friday, October 5. The presenters of the posters P1 through P58 are requested to be present at their posters.

P1 Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of the DESIR cohort

Sepriano A., Ramiro S., van der Heijde D., Dougados M., Claudepierre P., Feydy A., Reijnierse M., Loeuille D., Landewé R. (The Netherlands & France)

P2 Which scoring method depicts spinal radiographic damage in (early) axial spondyloarthritis best? Five-year results from the DESIR cohort

Ramiro S., Claudepierre P., Sepriano A., van Lunteren M., Molto A., Feydy A., d'Agostino M.A., Loeuille D., Dougados M., Reijnierse M., van der Heijde D. (The Netherlands & France)

P3 Spinal radiographic progression in early axial SpA: 5-year data from the DESIR cohort

Ramiro S., van der Heijde D., Sepriano A., van Lunteren M., Molto A., Feydy A., d'Agostino M.A., Loeuille D., Dougados M., Reijnierse M., Claudepierre P. (The Netherlands & France)

P4 Correlation between ultrasound nail changes on psoriatic disease and nail psoriasis severity index comparing with rheumatoid arthritis and healthy controls



Carneiro S., Gynszpan R., Moss I., Mendonça J.A., Fernandes M., Arnóbio A., Ramos-e-Silva M. (Brazil)

P5 Progression of structural damage on MRI of the spine and sacroiliac joints in patients with axial spondyloarthritis is limited: The 5-year results in the DESIR cohort


Madari Q.S.R., Ramiro M.S., Sepriano A., Landewé R., Dougados M., van Gaalen F.A., van der Heijde D. (The Netherlands, Portugal & France)

P6 Magnetic resonance imaging of the cervical spine in patients with rheumatoid arthritis and ankylosing spondylitis presenting with chronic neck pain – A systematic comparison of clinical assessments

Baraliakos X., Soltani M., Kiltz U., Braun J. (Germany)




- P7 Analysis of the different value of magnetic resonance imaging changes in the sacroiliac joints for a diagnosis of axial spondyloarthritis as judged by rheumatologists and radiologists**
Baraliakos X., Ghadir A., Fruth M., Kiltz U., Braun J. (Germany)
- P8 Inflammatory lesions and structural changes of sacroiliac joints on MRI in early axial spondyloarthritis: 2-year follow-up study**
Rumiantceva D.G., Dubinina T.V., Demina A.B., Erdes S. (Russia)
- P10 Diagnostic value of MRI in non-radiographic axial spondyloarthritis**
Rusman T., John M.L., van der Weijden M.A.C., Boden B.J.H., van der Bijl C.M.A., Bruijnen S.T.G., van der Laken C.J., Nurmohamed M.T., van der Horst-Bruinsma I.E. (The Netherlands)
- P11 The damage to the hip joints in ankylosing spondylitis according to X-ray examination**
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes Sh.F. (Russia)
- P12 MRI assessment of hip joints involvement in ankylosing spondylitis patients**
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes S.F. (Russia)
- P13 Factors associated with changes in volumetric bone mineral density in patients with ankylosing spondylitis - A five-year prospective study using HRpQCT**
Deminger A., Klingberg E., Lorentzon M., Carlsten H., Jacobsson L.T.H., Forsblad-d'Elia H. (Sweden)
- P14 The physiological changes of the enthesis in response to age, body mass index and physical activity - An ultrasound study in healthy people**
Ureyen S., Solmaz D., Stephenson W., Eder L., Roth J., Aydin S.Z. (Canada)
- P15 Optimizing the MRI imaging in patients with inflammatory back pain and suspected Axial Spondyloarthritis**
Chan A., Mills T., Yoong P. (UK)
- P16 Simple radiographic findings of Achilles tendon in symptomatic and asymptomatic posterior heel in Ankylosing Spondylitis**
Sung I.H., Kim T.H., Lee J.K. (Korea)
- P17 Diagnostic ascertainment of axial spondyloarthritis in patients presenting with undiagnosed back pain: What is the impact of MRI in rheumatological practice?**
Maksymowych W.P., Carmona R., Yeung J., Chan J., Martin L., Aydin S., Mosher D., Masetto A., Keeling S., Ziouzina O., Rohekar S., Paschke J., Carapellucci A., Lambert R.G. (Canada)
- P18 MRI lesion definitions in axial spondyloarthritis: A consensus reappraisal from the Assessments in SpondyloArthritis International Society (ASAS)**
Maksymowych W.P., Lambert R.G., Ostergaard M., de Hooge M., Pedersen S.J., Bennett A., Burgos-Vargas R., Eshed I., Landewe R., Machado P.M., Marzo-Ortega H., Hermann K.G., Poddubnyy D., Rudwaleit M., Sieper J., van der Heijde D., van der Horst-Bruinsma I., Weber U., Baraliakos X. (Denmark, Belgium, UK, Mexico, The Netherlands & Germany)
- P19 Ability of magnetic resonance imaging to predict remission and relapse in peripheral spondyloarthritis**
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)
- P20 Clinical evaluation correlates poorly with ultrasound and magnetic resonance imaging of joints and entheses in early peripheral spondyloarthritis**
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)
- P21 Consensus definitions for MRI lesions in the sacroiliac joints of patients with axial spondyloarthritis: First analysis from the assessments in spondyloarthritis international society classification cohort**
Maksymowych W.P., Pedersen S.J., Baraliakos X., Machado P., Weber U., Sieper J., Wíchuk S., Poddubnyy D., Ostergaard M., Paschke J., Lambert R.G. (Canada, Denmark, Germany & UK)



- P22 The contribution of structural MRI lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort**
Maksymowych W.P., Ostergaard M., Lambert R.G., Weber U., Pedersen S.J., Sieper J., Poddubnyy D., Wichuk S., Machado P., Paschke J., Baraliakos X. (Canada, Denmark, Germany & UK)
- P23 First validation of consensus definitions for MRI lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS) MRI group**
Maksymowych W.P., Weber U., Pedersen S.J., Baraliakos X., Machado P., Sieper J., Poddubnyy D., Wichuk S., Lambert R.G., Paschke J., Ostergaard M. (Canada, Denmark, Germany & UK)
- P24 Which MRI lesions in the sacroiliac joint are associated with the diagnosis of axial spondyloarthritis after 2 years follow up in the Echography in Spondyloarthritis Cohort (ECHOSPA)?**
Maksymowych W.P., Loeuille D., Wichuk S., Paschke J., Judet O., Breban M., D'Agostino M.A., Lambert R.G. (Canada & France)
- P25 MRI assessment of bone marrow edema in the sacroiliac joints of patients with spondyloarthritis: Is the SPAIR T2w technique comparable to STIR?**
Dalto V.F., Luppino-Assad R., Crema M.D., Louzada-Junior P., Nogueira-Barbosa M.H. (Brazil & USA)
- P26 Validation of a web-based calibration module for the SPARCC MRI SIJ inflammation score based on principles of artificial intelligence**
Maksymowych W.P., Krabbe S., Biko D.M., Weiss P., Maksymowych M., Cheah J., Kröber G., Weber U., Danebod K., Bird P., Chiowchanwisawakit P., Moeller J., Francavilla M., Stimec J., Kogay T., Zubler V., Batthish M., Winn N., Rumsey D., Guglielmi R., Pedersen S.J., Boutrup H., Shafer S., Jaremko J., Malik F., Heffernan E., Johansson M.P., Paschke J., Lambert R.G. (Canada, Denmark, USA, Australia, Thailand, Switzerland, UK & Ireland)
- P27 Can sufficient reliability of scoring SIJ structural lesions on MRI be achieved using a web-based calibration module developed on principles of artificial intelligence?**
Maksymowych W.P., Kröber G., Danebod K., Weiss P., Biko D.M., Weber U., Krabbe S., Maksymowych M.P., Cheah J., Bird P., Kogay T., Jaremko J., Zubler V., Chauvin N., Shafer S., Heffernan E., Guglielmi R., Winn N., Francavilla M., Pedersen S.J., Boutrup H., Paschke J., Lambert R.G. (Canada, Denmark, USA, Australia, Switzerland, Ireland & UK)
- P28 Computer-aided classification of inflammatory sacroiliitis in magnetic resonance imaging**
Calil Faleiros M., Jens Rivero Zavala E., Raniery Ferreira Junior J., Luppino-Assad R., Dalto V.F., Louzada-Junior P., Nogueira-Barbosa M.H., Azevedo-Marques P.M. (Brazil)
- P29 Sacroiliitis in patients with psoriatic arthritis and ankylosing spondylitis - Are there differences?**
Luppino-Assad R., de Oliveira R., Nogueira-Barbosa M.H., Louzada-Junior P., Dalto V.F., Sampaio-Barros P.D. (Brazil)
- P30 Radiomics association of MRI texture features with spondyloarthritis and sacroiliitis**
Luppino-Assad R., Magalhães Tenório A.P., Dalto V.F., de Oliveira R., Louzada-Junior P., Nogueira-Barbosa M.H., Azevedo-Marques P.M., Calil Faleiros M., Ferreira-Junior J.R., Yoshida H. (Brazil & USA)
- P31 Spondyloarthritis in a population without access to biologics in 2017 - Padre Hurtado Hospital experience**
Ibáñez S., Valenzuela O., Villar M., Silva F., Poblete M., Mogollones K., Mardones C. (Chile)
- P32 Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort**
van Lunteren M., Sepriano A., Landewé R., Sieper J., Rudwaleit M., van der Heijde D., van Gaalen F.A. (The Netherlands, Portugal & Germany)




- P33 Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known? Data from the ASAS, DESIR, and SPACE cohorts**
van Lunteren M., van der Heijde D., Sepriano A., Landewé R., Berg I.J., Dougados M., Gossec L., Jacobsson L., Ramonda R., Rudwaleit M., Sieper J., van Gaalen F.A. (The Netherlands, Portugal, Norway, France, Sweden, Italy & Germany)
- P34 Diagnostic delay in spondyloarthritis: How can we do better?**
Resende G.G., Lage R.C., Malheiro O.B., Guimarães D.L., Bomtempo C.A.S., Carvalho M.A.P. (Brazil)
- P35 Cardiac conduction disturbances in patients with ankylosing spondylitis—A Swedish longitudinal cohort study**
Bengtsson K., Klingberg E., Deminger A., Jacobsson L.T.H., Bergfeldt L., Forsblad-d’Elia H. (Sweden)
- P36 Factors related to health related quality of life in ankylosing spondylitis, overall and stratified by sex**
Law L., Beckman Rehnman J., Deminger A., Klingberg E., Jacobsson L.T.H., Forsblad-d’Elia H. (Sweden)
- P37 Osteonectin in cardiovascular risk in axial spondyloarthritis: A serological and genetic study**
Genre F., Rueda-Gotor J., Remuzgo-Martínez S., Irure-Ventura J., Corrales A., Portilla V., Pulito-Cueto V., Blanco R., Llorca J., Oejo-Vinyals J.G., López-Mejías R., González-Gay M.Á. (Spain)
- P38 *In vivo* phosphorylation of p38 in monocytes is enhanced, at the time of diagnosis, in patients with axial spondyloarthritis (axSpA)**
Kuuliala A., Kuuliala K., Koivuniemi R., Hämäläinen M., Moilanen E., Kautiainen H., Repo H., Leirisalo-Repo M. (Finland)
- P39 Association of IgA antibodies against CD74 with production of IL17A but not of TNF α in patients with active axial spondyloarthritis**
Baraliakos X., Kniesch K., Baerlecken N., Braun J., Witte T. (Germany)
- P40 Comparison of retention rates between tumor necrosis factor- α inhibitors in ankylosing spondylitis patients: Data from the Korean College of Rheumatology Biologics registry**
Kim H.A., Oh S., Park Y.B., Shin K. (South Korea)
- P42 Overexpression of macrophage migration inhibitory factor in patients with ankylosing spondylitis and its relation to sex, inflammation and treatment**
Kumar A., Do L., Hellman U., Forsblad-d’Elia H. (Sweden)
- P43 PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 antitrypsin may identify axSpA patients at risk of uveitis**
Reilly E., McGrogan A., Sengupta R. (UK)
- P44 Comparing disease status, symptomology, and clinical characteristics of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients in the United States**
Deodhar A., Hunter T., Sandoval D., Lobosco S., Moon R., Miligan G. (USA & UK)
- P45 Can smoking cause paradoxical findings in patients with psoriatic arthritis?**
Kiliç E., Kiliç G., Nas K., Dağlı A.Z., Tekeoğlu I., Kamanlı A. (Turkey)
- P46 Fatigue, health related quality of life and physiologic status in patients with psoriatic arthritis in remission or low disease activity according to different outcome measures**
Kiliç G., Kiliç E., Nas K., Kamanlı A., Tekeoğlu I. (Turkey)
- P47 Fecal calprotectin, a useful biomarker of microscopic bowel inflammation in patients with spondyloarthritis**
Campos J.F., Resende G.G., Lage J.A., Carvalho, S.C., Barbosa A.J.A., Ferrari M.L.A. (Brazil)
- P48 Undifferentiated spondyloarthritis in Brazilian patients - Predictors of persistent disease compared to remission after eight years of follow-up**
da Cruz Lage R., Bomtempo C.A.S., Kakehasi A.M., Carvalho M.A.P., Resende G.G. (Brazil)
- P49 Serum miR-214 as a novel noninvasive biomarker for ankylosing spondylitis**
Jin S.H., Kook H., Jin H.M., Cho Y.N., Lee S.S., Park Y.W., Kim T.J. (South Korea)



- P50 Do n-3 polyunsaturated fatty acids affect ECM remodeling in Psoriatic Arthritis?**
Sardar S., Kristensen S., Siebuhr A.S., Christensen J.H., Karsdal M.A., Schmidt E.B., Schlemmer A., Bay-Jensen A.C. (Denmark)
- P51 Impact of TNF inhibition on work outcomes, in Axial Spondyloarthritis**
Shim J., Jones G.T., Pathan E.J., Macfarlane G.J. (UK & Canada)
- P52 Patients awareness of the disease treatment, disease activity and spinal mobility monitoring before and after educational schools for rheumatologists and the patients with ankylosing spondylitis**
Lapshina S.A., Dubinina T.V., Gaydukova I.Z., Sitalo A.V., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.I., Ivanova O.N., Korotaeva T.V., Nesmeyanova O.B., Otteva E.N., Nikishinal P., Raskina T.A., Rebrov A.P., Rummyantseva O.A., Smirnov A.V., Erdes Sh.F. (Russia)
- P53 Serum Glucocorticoid-Inducible Kinase-1(SGK-1) levels in patients with Ankylosing Spondylitis**
Keskin G., Inal A., Keskin D., Olmez U. (Turkey)
- P54 Use of MRI and biological therapy in incident patients diagnosed as ankylosing spondylitis and spondyloarthritis: Danish nationwide cohort study 2000-2013**
Nygaard A., Ljungdahl P., Iachina M., Schiottz-Christensen B. (Denmark)
- P55 Disease activity and characteristics of SpA-patients fulfilling ESSG criteria only compared to SpA-patients fulfilling ASAS criteria**
Hansen I.M., Bakland G. (Norway)
- P56 Serum fibroblast growth factor-23 levels were higher in patients with axial spondyloarthritis and may be associated with disease activity**
Gercik O., Coban E., Ozbek Iptec B., Avcioglu G., Solmaz D., Bayindir O., Kabaday G., Kozaci D., Akar S. (Turkey)
- P57 Expression of biomarkers in Psoriatic Arthritis**
Juneblad K., Rantapää Dahlqvist S., Alenius G.M. (Sweden)
- P58 Association between high body mass index and clinical features of axial spondyloarthritis**
Yeo J.N., Seo M.R., Ryu H.J., Choi H.J., Baek H.J. (Republic of Korea)

Poster Session 2 is scheduled during the coffee break of 16.30 - 17.15 hrs on Friday, October 5. The presenters of the posters P59 through P112 are requested to be present at their posters.

- P59 Disease modifying anti rheumatic drugs in the treatment of SAPHO syndrome: Systematic literature analysis**
Monet M., Prati C., Guillot X., Sondag M., Verhoeven F., Aubin F., Wendling D. (France)
- P60 Treatment outcome with combined methotrexate, sulfasalazine and on-demand NSAIDs in axial spondyloarthritis in a resource-limited real world clinical practice**
Ganapati A., Pulukool S., Gowri M., Antonisamy B., Danda D. (India)
- P61 Certolizumab pegol in a Spanish cohort of patients with psoriatic arthritis - Preliminary results**
Reina D., Mateo L., Prior Á., Laiz A., Moreno M., Juanola X. (Spain)
- P62 Evaluation of the work productivity in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients before and after the start of adalimumab therapy in daily practice in Belgium (SpActive Study)**
De Clerck L., Maertens M., Remans Ph., Stuer A., Delmotte N., Van den Enden M., Stubbe M. (Belgium)
- P63 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in ankylosing spondylitis (COMPLETE-AS): 12-month data**
Bessette L., Khraishi M., Chow A., Pavlova V., Silverberg S., Stewart J., Remple V. (Canada)
- P64 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in psoriatic arthritis (COMPLETE-PsA): 12-month data**
Khraishi M., Bessette L., Chow A., Haraoui B., Pavlova V., Stewart J., Remple V. (Canada)
- P65 Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis**
Yahya F., Gaffney K., Sengupta R. (UK & Malaysia)



- P66 Efficacy of new treatments on dactylitis of psoriatic arthritis: Update of systematic literature review**
Sondag M., Verhoeven F., Guillot X., Prati C., Wendling D. (France)
- P68 Comparison of continuous use of NSAIDs and on-demand mode in patients with early axial spondyloarthritis**
Erdes S., Rumiantceva D.G., Dubinina T.V., Demina A.B. (Russia)
- P69 How to optimize exercise behaviour in axial spondyloarthritis - Results of an intervention mapping study**
Hilberdink S., Van Weely S.F.E., Van der Giesen F.J., Nijkamp M., Lopuhaä N., Vliet Vlieland T.P.M. (The Netherlands)
- P70 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: Results from the 48-week run-in part of C-OPTIMISE**
Landewé R., van der Heijde D., Dougados M., Baraliakos X., Van den Bosch F., Hoepken B., Thomas K., Gensler L.S. (The Netherlands, France, Germany, Belgium & USA)
- P71 Intravenous golimumab in adult patients with active psoriatic arthritis: Efficacy and safety through 1 Year**
Husni M.E., Kavanaugh A., Harrison D.D., Kim L., Lo K.H., Hsia E.C. (USA)
- P72 Weight-loss improves disease activity in patients with psoriatic arthritis and obesity**
Klingberg E., Bilberg A., Björkman S., Hedberg M., Jacobsson L., Forsblad-d'Elia H., Carlsten H., Eliasson B., Larsson I. (Sweden)
- P73 A flare of sacroiliitis under Vedolizumab Therapy for Crohn Disease**
Sunar İ., Yılmaz G., Yalçın A.P., Ataman Ş. (Turkey)
- P74 Predicting persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients**
Hunter T., Deodhar A., Bolce R., Schroeder K., Sandoval D. (USA)
- P75 Levels of adherence to biologic therapy of spondyloarthritis patients**
Madeira N., Cardoso A., Trinca R., Silva C., Santos H., Miguel C., Barcelos F., Medeiros D., Campanilho Marques R., Cunha M. (Portugal)
- P76 Secukinumab demonstrates a consistent safety profile over long-term exposure (up to 4 years) in patients with active ankylosing spondylitis - Updated pooled analysis of three phase 3 trials**
Deodhar A., Baraliakos X., Marzo-Ortega H., Sieper J., Martin R., Porter B., Shete A. (USA, Germany, UK & Switzerland)
- P77 Secukinumab sustains improvements in signs and symptoms in patients with psoriatic arthritis through 2 years (FUTURE 4)**
Everding A., Kivitz A., Nash P., Tahir H., Pellet P., Wang Yi., Pricop L., Abrams K. (Germany, USA, Australia, UK & Switzerland)
- P78 Secukinumab efficacy in psoriatic arthritis patients with or without enthesitis at baseline - Pooled analysis from two Phase-III trials over 2 years**
Wallman J. K., Schett G., McInnes I. B., Quebe-Fehling E., Rasouliyan L., Pricop L., Fasth A. E., Gaillez C. (Sweden, Germany, UK, Switzerland, Spain & USA)
- P79 Reducing avoidable Biologic drug wastage through collaboration between patients and care providers: The Leeds Spondyloarthritis Service experience**
Barr A., Pickles D., Fadl N., Dou J., Vandeveld C., Dubash S., Freeston J.E., Marzo-Ortega H. (UK)
- P80 Six-month treatment results for ustekinumab (UST) and TNF inhibitors (TNFi) in psoriatic arthritis (PsA) in Europe (PsABio-Study)**
Smolen J.S., Bergmans P., Bondareva I., de Vlam K., Gremese E., Joven-Ibáñez B., Korotaeva T.V., Nurmohamed M.T., Sfikakis P.P., Siebert S., Smirnov P., Theander E., D'Abrosca V., Gossec L. (Austria, Russia, The Netherlands, Sweden, Belgium, Italy, Spain, Greece, UK & France)
- P81 Immune response profiling reveals signaling networks mediating TNF-blocker function and predictors of therapeutic responses in spondyloarthritis patients**
Menegatti S., Rouilly V., Latis E., Yahia H., Leloup C., Miceli-Richard C., Dougados M., Bianchi E., Rogge L. (France)
- P82 Switching to biosimilars: What have we learned?**
Marona J., Gomes J.L., Rodrigues-Manica S., Lopes C., Costa T., Mourão A.F., Silva I., Costa M., Mateus M., Araújo M.P., Falcão S., Castelão W., Crespo C.L., Branco J.C., Pimentel-Santos F.M. (Portugal)



- P83 Monotherapy with biologics vs combined therapy in patients with Psoriatic Arthritis (Apsor) peripheral**
Montero D., Ruiz E., Fernández O., Torre I., Intxaurre A.R., Pérez C., Blanco J.M., Rivera N., Iburguegoitia O., Guerrero E., Calvo I., Galindez E., García-Vivar M.L. (Spain)
- P84 Is the clinical and therapeutic profile related to satisfactory response to apremilast in psoriatic arthritis?**
De la Morena I., Espinosa M., Godoy H., Martínez À., Santos C., Martínez A., Fernández M., Fernández-Llanio N., Palma D., Moreno M.J., Haro A., Conesa A., Calvo J. (Spain)
- P85 Impact of biologics on immune cells in Axial Spondyloarthritis**
Rosine N., Koturan S., Yahia H., Menegatti S., Leloup C., Bianchi E., Miceli-Richard C., Rogge L. (France)
- P86 A cross-sectional evaluation of a Brazilian spondyloarthritis single-center tertiary cohort: Clinical and treatment data**
Shimabuco A., de Moraes J.C.B., Sampaio-Barros P., Goldenstein-Schainberg C., Gonçalves C.R., Saad C.G.S. (Brazil)
- P87 Personalising care: Using infliximab drug trough and anti-drug antibody levels is a safe and cost effective treatment strategy in Spondyloarthritis**
Dubash S., Bryer D., Fitton J., Barr A., Vandeveld C., Marzo-Ortega H., Freeston J.E. (UK)
- P88 The effect of biologic disease-modifying antirheumatic drugs (bDMARDs) in targeting disease remission in Axial Spondyloarthritis (axSpa): A systematic literature review (SLR)**
Cruz-Machado A.R., Manica S.R., Silva J.L., Pimentel-Santos F.M., Tavares-Costa J., Vieira-Sousa E. (Portugal)
- P89 The GO-DACT protocol: A randomized controlled trial to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis, in MTX naïve psoriatic arthritis patients**
Vieira-Sousa E., Canhão H., Fonseca J.E. on behalf of the GO-DACT research team (Portugal)
- P90 Tumor necrosis factor inhibitors persistence in psoriatic arthritis patients**
Vieira-Sousa E., Eusébio M., Ávila-Ribeiro P., Khmelinskii N., Machado A.R., Martins-Rocha T., Bernardes M., Santos-Faria D., Leite Silva J., Santos H., Miguel C., Carvalho P., Costa T., Teixeira L., Meirinhos T., Nero P., Santos M.J. (Portugal)
- P91 Remission rates of biologic-treated spondyloarthritis and psoriatic arthritis patients**
Ávila-Ribeiro P., Lourenço-Teixeira R., Fonseca J.E., Vieira-Sousa E. (Portugal)
- P92 Dispensation of immunobiologicals in model of assisted therapy in the SUS reduces costs with immunobiological in ankylosing spondylitis**
Scomparin-Silverio L.R., Saad C.G.S., Souza F.H.C., Miozzi R., Ribeiro A.C.M., Waisberg M.G., Bonfiglioli K.R., Prado L.L., Teich V., Bonfá E., Moraes J.C.B. (Brazil)
- P93 Demyelination associated with anti-TNF α treatment in spondyloarthritis patients - A single-center experience**
Kougkas N., Vourakis G., Avgoustidis N., Mitsias P.D., Sidiropoulos P., Mastorodemos V.C., Bertsias G. (Greece & USA)
- P94 Psoriasis- and inflammatory bowel disease models co-operate with biomechanical stress in triggering mild joint inflammation**
Gulino G.R., Van Mechelen M., Lories R. (Belgium)
- P95 The JAK1 selective inhibitor filgotinib regulates both entheses and colon inflammation in a mouse model of psoriatic arthritis**
Robin-Jagerschmidt C., Lavazais S., Marsais F., Ongenaert M., Monjardet A., Cauvin A., Saccomani C., Parent I., Merciris D., Chanudet E., Blanqué R., Borgonovi M., Lepescheux L., Auberval M., Dupont S., Clément-Lacroix P., Galien R. (France)
- P96 mTOR blockade by rapamycin decreases arthritis and spondylitis development and severity in HLA-B27 transgenic rats**
Chen S., van Tok M., Pots D., Taurog J., van de Sande M., Baeten D., van Duivenvoorde L. (The Netherlands & USA)




- P97 Certolizumab pegol like mice equivalent reduces inflammation and bone damage in transmembrane TNF transgenic mice**
Vieira-Sousa E., Silva S.P., Vidal B., Lopes I.P., Canhão H., Fonseca J.E. (Portugal)
- P98 Exploring the ankylosing spondylitis-associated regulatory SNPs at the *RUNX3* locus**
Vecellio M., Cohen C.J., Fischer R., Wordsworth B.P. (UK)
- P99 Chronic back pain (CBP) in first degree relatives (FDR's) of patients with ankylosing spondylitis - Predictive value of HLA-B27 and persistence of the inflammatory back pain over time**
Reveille J.D., Lee M., Diekman L., Ward M.M., Gensler L.S., Tahanan A., Rahbar M.H., Weisman M.H. (USA)
- P100 Intracellular activity of protein phosphatase magnesium-dependent 1A regulates bone metabolism in ankylosing spondylitis**
Kim Y.G., Yoo B., Kim T.H., Chang E.J. (Korea)
- P101 IL-23 induction of MDL-1+ myeloid cells is critical in the pathogenesis of psoriatic arthritis**
Nguyen C.T., Hui D., Kang M., Gu R., Adamopoulos I.E. (USA)
- P102 Proteomic and transcriptomic profiling of cells in ankylosing spondylitis patients identifies a novel, synovial-resident CD8+ T cell**
Qaiyum Z., Gracey E., Yao Y., Inman R.D. (Canada)
- P103 Tyk2 promotes IL-23-induced type 3 immunity and disease progression in spondyloarthritis**
Gracey E., Muller M., Miao W., Westlin W., Inman R.D. (Canada, Austria & USA)
- P104 MicroRNAs deregulation in monocytes and CD4+ T-lymphocytes from patients with axial spondyloarthritis**
Fogel O., Bugge Tingaard A., Fagny M., Sigrist N., Roché E., Leclère L., Deleuze J.F., Dougados M., Tost J., Miceli-Richard C. (France & Denmark)
- P105 Development of a 19-parameter flow cytometry panel to analyze killer immunoglobulin-like receptor (KIR)-expressing lymphocytes in ankylosing spondylitis**
Sharma N., Lee J., Ermann J. (USA)
- P106 IL-22-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritis joint**
Blijdorp I.C.J., Van Mens L.J.J., Menegatti S., Chen S., Hreggvidsdottir H.S., Noordenbos T., Latuhihin T.E., Bernink J.H., Rogge L., Spits H., Baeten D.L.P., Yeremenko N.G. (The Netherlands & France)
- P107 Histological evidence that mast cells act as promoters rather than regulators of IL-17A-mediated tissue inflammation in spondyloarthritis**
Chen S., Noordenbos T., Blijdorp I., van Mens L., Ambarus C.A., Vogels E., te Velde A., Alsina M., Cañete J.D., Yeremenko N., Baeten D. (The Netherlands & Spain)
- P108 ROR γ t inhibition selectively targets pathogenic subsets of human iNKT and $\gamma\delta$ -T cells enriched in Spondyloarthritis while preserving IL-22 responses**
Venken K., Mortier C., Labadia M.E., Jacques P., Decruy T., Coudenys J., Hoyt K., Van Gassen S., Wahle J., Saeys Y., Van Den Bosch F., Nabozny G., Elewaut D. (Belgium & USA)
- P109 Screening for antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets**
Quaden D., Vandormael P., Corten K., Vandenabeele F., Vanhoof J., Geusens P., Somers V. (Belgium & The Netherlands)
- P110 A probable role of HSP60 in the pathogenesis of spondyloarthritis**
Romero-López J.P., Domínguez-López M.L., Jiménez-Zamudio L., Burgos-Vargas R., García-Latorre E. (Mexico)
- P111 An enthesal innate immune cell biological basis for differential efficacy of PDE4 and IL-23 pathway blockade between Psoriatic Disease and Rheumatoid Arthritis**
Bridgwood C., Cuthbert R., Watad A., Palmer T., Russell T., Dunsmuir R., Khan A., Wittmann M., McGonagle D. (UK & Israel)
- P112 Regulation of cytokine production by iNKT cells requires IRE1 α**
Govindarajan S., Gaublotte D., Cruyssen R.V.D., Verheugen E., Gassen S.V., Saeys Y., Tavernier S., Iwawaki T., Bloch Y., Savvides S.N., Janssens S., Lambrecht B.N., Drennan M.B., Elewaut D. (Belgium & Japan)




Poster Session 3 is scheduled during the coffee break of 10.35 - 11.15 hrs on Saturday, October 6. The presenters of the posters P113 through P166 are requested to be present at their posters.

- P113 Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis**
Lee K.A., Kim H.R., Lee S.H. (South Korea)
- P114 Performance of referral strategies for spondyloarthritis: A population-based nationwide study**
Sepriano A., Ramiro S., Araújo F., Machado P.M., Rodrigues A., Gouveia N., Eusébio M., Canhão H., Branco J. (Portugal, The Netherlands & UK)
- P115 Integrated longitudinal analysis increases precision and reduces bias: A comparative 5-year analysis in the DESIR Cohort**
Sepriano A., Ramiro S., van der Heijde D., Dougados M., Claudepierre P., Feydy A., Reijnierse M., Loeuille D., Landewé R. (The Netherlands & France)
- P116 High prevalence of axial spondyloarthritis in patients with anterior uveitis and chronic back pain – Preliminary results of the Sp-EYE study**
van Bentum R.E., Verbraak F.D., Wolf S., Tan H.S., van der Horst-Bruinsma I.E. (The Netherlands)
- P117 Computer tomography defined sacroiliitis in Inflammatory Bowel Disease – A service evaluation of reporting standards**
Lim C.S.E., Low B.L.S., Dhillon B., Azegami S., Toms A., Gaffney K. (UK)
- P118 Comparison of work disability, depression, and quality of life in ankylosing spondylitis vs psoriatic arthritis: Interim results from the COMPLETE studies**
Khraishi M., Bessette L., Haraoui B., Florica B., Setty Y., Teo M., Remple V. (Canada)
- P119 Impact of extra-articular manifestations on patient-reported outcomes in ankylosing spondylitis and psoriatic arthritis: Interim results from the COMPLETE studies**
Bessette L., Khraishi M., Florica B., Setty Y., Teo M., Remple V. (Canada)

- P120 Asas consensus on Spanish nomenclature for spondyloarthritis**
Navarro-Compán V., Otón T., Loza E., Almodóvar R., Ariza-Ariza R., Bautista-Molano W., Burgos-Vargas R., Collantes-Estévez E., de Miguel E., González-Fernández C., Gratacós J., Ibáñez S., Juanola X., Maldonado-Cocco J., Moltó A., Mulero J., Pacheco-Tena C., Ramos-Remus C., Sanz-Sanz J., Valle-Oñate R., Zarco P., Marzo-Ortega H. (Spain, Colombia, Mexico, Chile, Argentina, France & UK)
- P121 Comparison of clinical and imaging arms of the Assessment of Spondyloarthritis International Society (ASAS) classification criteria and parameters of objective inflammation in patients with non-radiographic axial spondyloarthritis (nr-axSpA)**
Landewé R., Sieper J., Deodhar A., Marzo-Ortega H., Lambert R.G., Li M., Wang X., Anderson J.K. (The Netherlands, Germany, USA, UK & Canada)
- P122 Spinal mobility measures allow discrimination of subgroups of different activity and severity in early axial spondyloarthritis**
Marques M.L., Ramiro S., van Gaalen F.A., Goupille P., Dougados M., van der Heijde D. (The Netherlands, Portugal & France)
- P123 Measuring spinal mobility over time in early axial spondyloarthritis: Can we do it reliably?**
Marques M.L., Ramiro S., van Gaalen F.A., Goupille P., Dougados M., van der Heijde D. (The Netherlands, Portugal & France)
- P124 Influence of inflammation and structural damage on global functioning in patients with axial spondyloarthritis - Using the ASAS Health Index in routine care**
Kiltz U., Wiatr T., Baraliakos X., Fedorov K., Braun J. (Germany)
- P125 Osteoporosis commonly occurs in axial spondyloarthropathy**
Fitzgerald G.E., Anachebe T., McCarroll K., O' Shea F. (Ireland)
- P126 Syndesmophytes prevent accurate DXA assessment of the spine in axial spondyloarthropathy**
Fitzgerald G.E., Anachebe T., McCarroll K., O' Shea F. (Ireland)
- P127 Add-on effect of aerobic exercise to stretching in patients with ankylosing spondylitis**
Kim H.W., Park J., Kim D., Park J.H., Park M.C. (Korea)




- P128 Assessment of early myocardial dysfunction using speckle tracking echocardiography in patients with radiographic and nonradiographic axial spondyloarthritis**
Emren V., Gercik O., Ozdemir E., Solmaz D., Gucenmez S., Eren N., Tokac M., Kabadayi G., Akar S. (Turkey)
- P129 ASAS, BASDAI and ASDAS remission in secukinumab treated patients with active ankylosing spondylitis: 3-year results from a pooled analysis of two phase 3 studies**
Baraliakos X., Van den Bosch F., Machado P., Gensler L., Bintu S., Porter B., Gaillez C., Deodhar A. (Germany, Belgium, UK, USA & Switzerland)
- P130 The European Map of Axial Spondyloarthritis (EMAS) - Living with the condition**
Garrido-Cumbrera M., Navarro-Compan V., Gálvez-Ruiz D., Gossec L., Bundy C., Mahapatra R., Makri S., Plazuelo-Ramos P., Delgado Dominguez C.J., Poddubnyy D. (Spain, France, UK, Cyprus & Germany)
- P132 Assessing functional disability and general health situation in patients with Ankylosing Spondylitis by ASAS health index**
Can M. (Turkey)
- P133 Empowering Ankylosing Spondylitis (AS) patients through an online personal health system**
Eren O., Gençtürk M., Yüksel M. (Turkey)
- P134 Prevalence and characterization of psoriatic arthritis mutilans patients from a single tertiary center**
Oliveira J.L., Cordeiro R.A., Carrasco S., Gonçalves C.R., Moraes J.C.B., Saad C.G.S., Sampaio-Barros P.D., Goldenstein-Schainberg C. (Brazil)
- P135 The status of health in patients with axial spondyloarthritis (axSpA) as determined by the Assessment of SpondyloArthritis International Society Health Index (ASAS-HI)**
Alva Medina G., Pelaez-Ballestas I., Burgos Vargas R., Avila Valde R., Bañuelos Ramírez D., Barbosa Cobos R.E., Barrera Guerra R.C., Barrera Rodríguez A.A., Barrera Vargas A., Bernard Medina A.G., Casasola Vargas J.C., Castillo Ortíz J.D., Chávez López M.A., Cruz Alvarez L.J., Durán Barragán S., Durán Ortíz J.S., Enríquez Sosa F.E., Espinosa Morales R., Espinosa Villalpando J., Flores Alvarado D.E., Gámez Nava J.I., García Méndez S., García Morales H., García Olivera I., González Díaz V., González López L.C., González Pérez D.T., Gordillo Huerta M.V., Gutiérrez Ureña S.R., Hernández Cuevas C.B., Hernández Paz R., Lamuño Encorrada M., Macias Palacios M., Maradiaga Ceceña M.A., Marines Castillo A.L., Martinez Bonilla G.E., Martínez Valles M.A., Medrano Ramírez G., Mendoza Fuentes A., Meoño Morales E.E., Merayo Chalico F.J., Miranda Hernandez D.G., Miranda Limón J.M., Mota Mondragón B.A., Muñoz López S., Muñoz Monroy O.E., Navarro Zarza J.E., Pacheco Tena C.F., Palafox Sánchez C.A., Pérez Vázquez M.E., Pizaña Serna A.M., Ramírez Assad M.C., Ramos Remus C.R.D., Reyes Cordero G.C., Rodríguez García F., Saavedra Salinas M.A., Sandoval García L.F., Santana Portillo N.M., Silveira Torre L.H., Solís Alvarado C.M., Vazquez del Mercado Espinosa M., Veloz Aranda J.A., Zazueta Montiel B.E. (Mexico)
- P136 Is the delay from recognition of severe active axial spondyloarthritis to biologic disease modifying therapy initiation improving?**
Williams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)
- P137 Axial spondyloarthritis-related quality of life improves significantly following initiation of biological disease-modifying therapy**
Williams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)
- P138 Work productivity among workers with axial spondyloarthritis**
Lopes C., Rodrigues-Manica S., Marona J., Mateus M., Pimentel-Santos F., Branco J. (Portugal)
- P139 Improvement of cytological grade and tear production in Ankylosing Spondylitis patients under anti-TNF therapy: A long-term follow-up**
Usuba F.S., Saad C.G.S., Novaes P., Santo R.M., Moraes J.C.B., Bonfá E., Alves M.R. (Brazil)




- P140 Emergence of severe spondyloarthropathy related enthesal pathology in Vedolizumab treated Inflammatory Bowel Disease**
Dubash S., Thirupathy M., Tinazzi I., Al Araimi T., Pagnoux C., Weizman A.V., Richette P., Tran Minh M.L., Allez M., Singh A., Ciccio F., Hamlin J., Tan A.L., Marzo-Ortega H., McGonagle D. (UK, Italy, Canada & France)
- P141 Patient-acceptable symptom state in psoriatic arthritis: Prevalence and associated factors in real clinical practice**
Queiro R., Cañete J.D., Montilla C., Abad M.A., Gómez S., Cabez A. (Spain)
- P142 Vitamin D deficiency is associated with greater presence of vertebral fractures, in patients with axial spondyloarthritis**
Romera-Lopez C., Fernández-Carballido C., Martínez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)
- P143 Osteoporosis and vertebral fractures are associated with disease activity and axial radiographic damage in axial spondyloarthritis - 206 Spanish patient's series**
Romera-López C., Fernández-Carballido C., Martínez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)
- P144 Validity of PROMIS measures in ankylosing spondylitis patients**
Hwang M.C., Ogdie A.R., Reveille J.D. (USA)
- P145 Patients with axial spondyloarthritis rarely have 1 or 2 inflammatory back pain parameters**
de Hooge M., Varkas G., Elewaut D., van den Bosch F. (Belgium)
- P147 Diagnostic performance of power Doppler ultrasound of the entheses in patients with uncertain diagnosis of spondyloarthritis: The EchoSpA prospective multicenter French cohort**
D'Agostino M.A., Aegerter P., Loeuille D., Judet O., Chary-Valckenaere I., Saraux A., Marcelli C., Guis S., Gaudin P., Jousse-Joulin S., Amor B., de Vlaminck K., Falgarone G., Said-Nahal R., Breban M. (France & Belgium)
- P149 A study of the HLA-B*27-associated microbiota in healthy individuals reveals intestinal dysbiosis and an altered microbiota-specific immune response may be predisposing events in the pathophysiology of spondyloarthritis**
Asquith M., Sternes P., Costello M.E., Schleisman M., Davin S., Diamond S., Karstens L., Brown M.A., Rosenbaum J.T. (USA & Australia)
- P150 A study of microbial translocation in an animal model of spondyloarthritis**
Asquith M., Schleisman M., Davin S., Stauffer P., Karstens L., Rosenbaum J.T. (USA)
- P151 The response to TNF-blockers treatment of SpA patients is influenced by the interplay between HLA-B27 and gut microbiota composition at baseline**
Vallier M., Dougados M., Ferreira S., Menegatti S., Bianchi E., Rogge L., Chamaillard M., Miceli-Richard C. (France)
- P152 Fungi overlooked: The mycobiome as a cause of spondyloarthritis (SpA)**
Rosenbaum J.T., Laurence M., Asquith M.J. (USA & Canada)
- P153 Specific alterations in the enteric virome in the subclinical gut inflammation of AS patients drive innate immune alterations**
Ciccio F., Guggino G., Macaluso F., Rizzo A. (Italy)
- P154 Is calprotectin a useful diagnostic tool in diagnosing spondyloarthropathies?**
Van Hoovels L., Schiemsky T., Cauchie M., Van Den Bremt S., Vander Cruyssen B., Bossuyt X., Stubbe M. (Belgium)
- P155 Features of chronic pain syndrome in patients with ankylosing spondylitis**
Filatova E.S., Erdes S. (Russia)
- P156 Efficiency of long term educational programs for physicians in early diagnosis and treatment of axial spondyloarthritis in Kazan**
Lapshina S., Myasoutova L. (Russia)
- P157 Preliminary results of development and 12 months follow up test of the mobile application for patients with axial spondyloarthritis**
Rumiantceva D.G., Dubinina T.V., Sitalo A.V., Erdes S. (Russia)
- P158 Pain beliefs and disability in chronic "inflammatory" and "non-inflammatory" low back pain**
Yilmaz Z. (Turkey)
- P159 Rapid onset of efficacy in patients with active psoriatic arthritis treated with Ixekizumab: A pooled analysis of data from two phase III clinical trials**
Deodhar A., Papp K., Shuler C.L., Park S.Y., Kvien T. (USA, Canada & Norway)



- P160 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life (QoL) in patients with active psoriatic arthritis (PsA)**
Kavanaugh A., Birt J., Lin C-Y., Benichou O., Hufford M.M., Gottlieb A.B., Van Beneden K. (USA & Belgium)
- P161 Health utility estimates in economic evaluations in axial spondyloarthritis – Different methods, different results**
Jones G.T., Macfarlane G.J., Pathan E.J., McNamee P., Neilson A.R. (UK & Canada)
- P162 Fibrodysplasia Ossificans Progressiva as a clinical model of new bone formation**
Nikishina I., Latypova A., Arsenyeva S., Kaleda M., Alekseev D. (Russia)
- P163 Russian Spondyloarthritis assessment groups' definition and criteria of remission in Axial Spondyloarthritis**
Gaydukova I.Z., Lapshina S.A., Dubinina T.V., Sitalo A.V., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.I., Ivanova O.N., Korotaeva T.V., Nesmeyanova O.B., Otteva E.N., Nikishina I.P., Raskina T.A., Rebrov A.P., Rummyantseva O.A., Smirnov A.V., Erdes Sh.F. (Russia)
- P164 Assessment of lumbar spinal mobility using inertial measurement units in axial spondyloarthritis**
Franco L., Ward W., Sengupta R., Cazzola D. (UK)
- P165 The prevalence of rheumatological diseases and psoriasis in the first-degree relatives of PsA patients**
Nas K., Çevik R., Dağlı A.Z., Tekeoglu I., Kamanli A., Sağ S. (Turkey)
- P166 Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis - Comparison with healthy controls**
Ulus Y., Akyo, Y., Bilgici A., Kuru O. (Turkey)



GENERAL INFORMATION






Inspired by patients.
Driven by science.

Leading and Innovating in axSpA


Addressing key
unmet needs...



...through innovative
clinical study designs...



...and advancing the understanding of
the role of IL-17 family of cytokines in
immune-inflammatory conditions



Visit us at the UCB booth # 1
to find out more

© UCB Biopharma SPRL, 2018. All rights reserved.
HQ/0818/CI/00101a. Date of preparation: August 2018.

As of 15/09/'18

Participant MD	€ 700,00
Researcher Non-MD with Abstract*	€ 400,00
Student with Abstract*	€ 400,00
Industry Participant	€ 900,00
Gala Dinner on Friday, October 5**	€ 75,00

**Presenting author only*

***If seats are available*

The registration includes

The registration fee includes access to all lectures, to the Opening Reception and Walking Dinner, the lunches, coffee breaks and the Farewell Reception as indicated in the programme. Participants also have free access to the exhibition.

Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory.

Separate registration and payment is required to participate in the Gala Dinner.

Payment

Payment is to be made by credit card. All major credit cards are accepted.

Cancellations

Cancellations received no later than August 31, 2018, entitle registered persons to a 50% refund. In order to cancel your registration and/or hotel booking please contact Laurence Schepens: laurence@medicongress.com.



**SOLVING THE
WORLD'S
TOUGHEST HEALTH
CHALLENGES
TAKES ALL OF US.**


It takes the will to find a new way forward.
And no one gets there alone.

That's why AbbVie teams with peers,
academics, clinical experts and others to
take on the most complex health challenges.

Uniting the best of pharma with the
boldness of biotech, together we're going
beyond conventional thinking to innovate
end-to-end approaches that make a real
difference.

Starting with science, we arrive at solutions
that help millions of patients around the
world live better.

abbvie.com



PEOPLE. PASSION.
POSSIBILITIES.

abbvie



Opening Reception and Walking Dinner on Thursday, October 4

This Opening Reception and Walking Dinner will take place at Opera Gent and is included in the registration fee. Pre-registration however is required.

Gala Dinner on Friday, October 5



The Gala Dinner will take place at the 'Handelsbeurs', an impressive building with a commanding façade.

The Handelsbeurs is located on the Kouter square, well-known for its 19th century stately buildings and for its flower market on Sundays. The Handelsbeurs is located at a mere stone's throw from Opera Gent.

Separate registration and payment is required to participate in the Gala Dinner.

Farewell Reception on Saturday, October 6


The Farewell Reception will take place at Opera Gent and is included in the registration fee. Pre-registration however is required.



Come to the Janssen R&D booth!

You can learn more about the Janssen programme in rheumatology

Location: Foyer of the Opera House



With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
 Janssen Pharmaceutica NV
 Turnhoutseweg 30
 B-2340 Beerse, Belgium
 Date of preparation: September 2018
 PHEM/IMM/0918/0006a



Venue

Opera Gent
 Schouwburgstraat 3, 9000 Gent
<https://operaballet.be/en>

Opera Gent is located in the city centre, within walking distance from the hotels.

It is strictly forbidden to take drinks/food into the meeting room.

Date

Thursday, October 4 - Saturday, October 6, 2018

Language

The official congress language is English.

Exhibition

A medical exhibition is held on the occasion of the Congress and is located on the 2nd floor. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Catering

Coffee breaks and lunches will be served in the exhibition area located on the 2nd floor.

WiFi

Free WiFi is offered to all participants and exhibitors. The WiFi access code will be available on-site.

Liability

Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration

MEDICONGRESS
 Noorwegenstraat 49
 B-9940 Evergem, Belgium
 Phone: +32 (0)9 218 85 85
 Fax: +32 (0)9 344 40 10
 Email: congresses@medicongress.com



Programme developed in collaboration with Wonder Reizen, Lic. A 5603





Platinum Sponsors




Gold Sponsors



Silver Sponsors





Novartis: Supporting the rheumatology community to improve patients' lives



Initiating
non-interventional
studies



Collaborating with
national registries



Cooperating with the
rheumatology community to
better understand remission



Introducing innovation and
technology into our clinical
trial designs



Supporting medical
education initiatives



Partnering to further
understand the basic
research needs
of disease



Launching imaging
preceptorship
programs
(e.g., **PsA Advances in
Imaging & Clinical
Evaluation**)